COPENHAGEN, Denmark – December 12, 2025 — Genmab has completed its tender offer to acquire outstanding common shares of Merus N.V., marking a transformative step in the company’s long-term growth strategy and the evolution of its oncology-focused antibody therapeutics portfolio. With 94.2% of Merus shares tendered and a subsequent offering period now open, Genmab positions itself to fully integrate Merus and accelerate the development of petosemtamab, a late-stage oncology asset with two Breakthrough Therapy Designations.
Science Significance
The acquisition brings the promising investigational therapeutic petosemtamab into Genmab’s pipeline, strengthening a portfolio already centered on innovative antibody engineering technologies. Petosemtamab’s demonstrated potential in head and neck cancer, combined with Genmab’s expertise in bispecific antibodies, immune-modulating agents, and effector-enhanced antibody formats, positions the therapy as a future best-in-class advancement. By expanding late-stage development and exploring multiple therapeutic lines, Genmab reinforces its scientific trajectory toward delivering next-generation oncology solutions capable of reshaping treatment paradigms.
Regulatory Significance
With petosemtamab already benefiting from dual Breakthrough Therapy Designations, Genmab is poised to navigate an expedited regulatory pathway, subject to forthcoming trial results. The company anticipates launching the therapy in 2027, pending successful clinical outcomes and approval processes. The acquisition supports Genmab’s regulatory strength by consolidating ownership over a high-value asset and streamlining the alignment of clinical strategy, submission planning, and global regulatory engagement, thereby improving the efficiency of interactions with agencies such as the FDA and EMA.
Business Significance
Advertisement
Genmab’s tender offer, valued at $97 per share, is projected to be accretive to EBITDA by 2029, reflecting the company’s confidence in petosemtamab’s multi-billion-dollar revenue potential. This acquisition supports Genmab’s shift toward a fully owned product model, diversifying revenue streams and accelerating its transformation into a global biotechnology leader. With 94.2% of shares tendered and a subsequent offering period extending to December 29, 2025, Genmab is positioned to finalize full acquisition and unlock long-term commercial value across oncology markets worldwide.
Patients’ Significance
For patients with head and neck cancer, especially those facing limited therapeutic options, petosemtamab represents a significant clinical advancement. Genmab’s decision to broaden and accelerate development underscores the therapy’s potential to deliver meaningful survival and quality-of-life improvements. As the company advances petosemtamab through late-stage trials, patients may gain earlier access to a treatment designed to extend benefits beyond existing immuno-oncology frameworks, promising more effective, differentiated antibody therapeutics.
Policy Significance
This acquisition aligns with global policy efforts supporting innovation in oncology, faster regulatory pathways, and greater access to life-altering cancer therapies. Breakthrough Therapy Designations signal a high-priority regulatory environment, enabling swift development and review. Genmab’s expansion of manufacturing, clinical infrastructure, and commercialization planning supports broader policy goals of expanding equitable access, enhancing supply chain resilience, and accelerating delivery of advanced biologics to patients across international markets.
Genmab’s completion of the tender offer for Merus and the subsequent integration of petosemtamab represents a decisive milestone in shaping its next decade of scientific and commercial evolution. With strong clinical promise, regulatory momentum, financial scalability, and a clear commitment to accelerating access to innovative antibody therapeutics, Genmab continues to reinforce its vision of transforming the lives of patients through high-impact, next-generation oncology medicines.
Source: Genmab A/S press release
